Currently, iPSC reprogramming methods can be divided into integrating reprogramming technologies (such as lentiviruses and retroviruses) and non-integrating reprogramming technologies (such as episomal vectors, Sendai virus, mRNA, and other small molecules) based on whether transcription factors are integrated into the cellular genome. Different reprogramming technologies have their own characteristics in terms of reprogramming efficiency, material preparation, delivery processes, and safety.

All cells in the body seem to have the potential to be induced pluripotent stem cells, but with varying efficiencies. Additionally, partially preserved epigenetic states can be maintained after reprogramming. Although this memory can be eliminated through long-term culture, it can affect the differentiation potential of induced pluripotent stem cells. The original cell type also affects the choice of gene delivery method, as it influences the efficiency of gene delivery.

"Yuanvore Program": in terms of cell reprogramming, we combine cutting-edge gene editing technology and small molecule reprogramming screening platform to develop an efficient and stable non-integrated reprogramming technology platform with independent intellectual property rights. In the process of obtaining iPS cells, not only the efficiency is greatly improved, but also the quality of iPS cells becomes more stable.

In the process of cell differentiation, there are many problems, such as low efficiency, long time, many non-target cells and so on, which make the production cost of cell drugs high and the therapeutic effect unstable. 

"Yuanvore Program": on the one hand, we use genomics to screen key growth factors that can effectively promote iPS cells to differentiate into target phenotypes; at the same time, we combine other disciplines and technologies on the basis of traditional developmental biology to efficiently improve the efficiency of cell differentiation. At the same time, the quality, effectiveness and safety of differentiated cells will also enhance the effectiveness of clinical treatment.

There is often a pathological environment in the area of cell transplantation, and the survival rate after cell transplantation is low; at the same time, the immunomodulatory ability of MSC cells is limited, so it is difficult to guarantee the therapeutic effect. 

"Yuanvore Program": the engineering transformation of the obtained cellular drugs has both "double positive effects". One is to effectively improve the adaptability of cells to the pathological environment in vivo to enhance the survival ability of drug cells in vivo, and the other is to fully enhance the secretion of extracellular factors. through the secretion of cytokines to start human tissue / organ self-repair mechanism, regulate the body immune balance and so on.